Sažetak
Uvod. Karcinom prostate je jedan od najčešćih malignih oboljenja kod muškaraca. Najčešći tip je adenocarcinom prostate. Karcinom malih ćelija prostate (KMĆP) obično se javlja u kombinaciji sa adenokarcinom prostate. Prikaz bolesnika. Prikazan je 72-godišnji bolesnik sa simptomima otežanog pražnjenja mokraćne bešike. Inicijalni nivo prostata specifičnog antigena (PSA) bio je 2,87 ng/mL. Uzeto je dvanaest bioptata prostate i u šest je otkriveno maligno tkivo. Analizirano tkivo najviše je odgovaralo “karcinomu malih ćelija”. Scintigrafija skeleta nije otkrila širenje karcinoma u skeletnom sistemu. Kompjuterizovana tomografija (KT) male karlice nije otkrila infiltraciju okolnog tkiva tumorom. Bolesnik je operisan – urađena je radikalna retropubična prostatektomija. Patohistološka analiza pokazala je slabo diferentovani adenokarcinom prostate sa zonama karcinoma malih ćelija [Gleason skor 5 + 5 (10), razred II, pT3bN1, stadijum IV]. Zaključak. Slabo diferentovan adenokarcinom prostate, posebno u kombinaciji sa karcinomom malih ćelija, jeste agresivan maligni tumor koji je u većini slučajeva povezan sa opsežnim širenjem bolesti u trenutku postavljanja dijagnoze i ima lošu prognozu. KMĆP izuzetno su retki tumori neuroendokrinog porekla. Bolesnici sa mešovitim karcinomom prostate imaju bolju prognozu i veću stopu preživljavanja. Trenutno ne postoje vodiči zasnovani na dokazima za lečenje ove vrste karcinoma prostate.
Ključne reči
Array
Array
Array
Array
Array
Reference
Nwaneri AC, McBeth L, Hinds TD Jr. Prostate Cancer in Afri-can American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling. Horm Cancer 2016; 7(5–6): 296–304.
Têtu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. Small cell carcinoma of the prostate. Part I. A clinico-pathologic study of 20 cases. Cancer 1987; 59(10): 1803–9.
Aparicio A, Tzelepi V. Neuroendocrine (small-cell) carcinomas: why they teach us essential lessons about prostate cancer. On-cology (Williston Park) 2014; 28(10): 831–8.
Palmgren JS, Karavadia SS, Wakefield MR. Unusual and un-derappreciated: small cell carcinoma of the prostate. Semin Oncol 2007; 34(1): 22–9.
Abbas F, Civantos F, Benedetto P, Soloway MS. Small cell carci-noma of the bladder and prostate. Urology 1995; 46(5): 617–30.
Humphrey PA. Histological variants of prostatic carcinoma and their significance. Histopathology 2012; 60(1): 59–74.
Farach A, Ding Y, Lee M, Creighton C, Delk NA, Ittmann M, et al. Neuronal Trans-Differentiation in Prostate Cancer Cells. Prostate 2016; 76(14): 1312–25.
Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. The spec-trum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book 2015: 92–103.
Deorah S, Rao MB, Raman R, Gaitonde K, Donovan JF. Survival of patients with small cell carcinoma of the prostate during 1973–2003: a population-based study. BJU Int 2012; 109(6): 824–30.
Wenk RE, Bhagavan BS, Levy R, Miller D, Weisburger W. Ec-topic ACTH, prostatic oat cell carcinoma, and marked hyper-natremia. Cancer 1977; 40(2): 773–8.
Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A et al. Results of a phase II study with doxorubicin, etopo-side, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002; 20(14): 3072–80.
Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992; 147(3 Pt 2): 935–7.
Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term out-comes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol 2013; 64(2): 307–13.
Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mos-quera JM, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012; 30(36): e386–9.
Mosquera JM, Beltran H, Park K, MacDonald TY, Robinson BD, Tagawa ST, et al. Concurrent AURKA and MYCN gene am-plifications are harbingers of lethal treatment-related neuro-endocrine prostate cancer. Neoplasia 2013; 15(1): 1–10.